Xvivo Perfusion AB logo

XVIVO - Xvivo Perfusion AB Share Price

SEK185.4 1.6  0.9%

Last Trade - 2:53pm

Mid Cap
Market Cap £429.4m
Enterprise Value £417.9m
Revenue £17.0m
Position in Universe 443rd / 1782
Unlock XVIVO Revenue
Relative Strength (%)
1m +6.61%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.97%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
84.7 120.2 138.2 148.3 187.9 220.8 227 350 +21.1%
-41.6 -0.7 -30.9 +103.3 +43.9 -61.4 +141.5 +322.2
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Xvivo Perfusion AB revenues decreased 26% to SEK76.8M. Net loss totaled SEK9.5M vs. income of SEK1.9M. Revenues reflect Durable Goods segment decrease of 26% to SEK72.2M, Non-Durable Goods segment decrease of 31% to SEK4.7M. Net loss reflects Depreciation/Amortization in R&D increase of 39% to SEK10M (expense), Depreciation/Amortization in SGA increase of 59% to SEK1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


XVIVO Revenue Unlock XVIVO Revenue

Net Income

XVIVO Net Income Unlock XVIVO Revenue

Normalised EPS

XVIVO Normalised EPS Unlock XVIVO Revenue

PE Ratio Range

XVIVO PE Ratio Range Unlock XVIVO Revenue

Dividend Yield Range

XVIVO Dividend Yield Range Unlock XVIVO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
XVIVO EPS Forecasts Unlock XVIVO Revenue
Profile Summary

Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since October 8, 2012
No. of Shareholders: 5,483
No. of Employees: 60
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 26,600,496
Free Float (0.0%)
Eligible for
XVIVO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for XVIVO
Upcoming Events for XVIVO
Friday 23rd October, 2020
Q3 2020 Xvivo Perfusion AB Earnings Call
Thursday 28th January, 2021
Full Year 2020 Xvivo Perfusion AB Earnings Call
Frequently Asked Questions for Xvivo Perfusion AB
What is the Xvivo Perfusion AB share price?

As of 2:53pm, shares in Xvivo Perfusion AB are trading at SEK185.4, giving the company a market capitalisation of £429.4m. This share price information is delayed by 15 minutes.

How has the Xvivo Perfusion AB share price performed this year?

Shares in Xvivo Perfusion AB are currently trading at SEK185.4 and the price has moved by 9.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Xvivo Perfusion AB price has moved by 13.85% over the past year.

What are the analyst and broker recommendations for Xvivo Perfusion AB?

Of the analysts with advisory recommendations for Xvivo Perfusion AB, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Xvivo Perfusion AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Xvivo Perfusion AB next release its financial results?

Xvivo Perfusion AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Xvivo Perfusion AB dividend yield?

Xvivo Perfusion AB does not currently pay a dividend.

Does Xvivo Perfusion AB pay a dividend?

Xvivo Perfusion AB does not currently pay a dividend.

When does Xvivo Perfusion AB next pay dividends?

Xvivo Perfusion AB does not currently pay a dividend.

How do I buy Xvivo Perfusion AB shares?

To buy shares in Xvivo Perfusion AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Xvivo Perfusion AB?

Shares in Xvivo Perfusion AB are currently trading at SEK185.4, giving the company a market capitalisation of £429.4m.

Where are Xvivo Perfusion AB shares listed? Where are Xvivo Perfusion AB shares listed?

Here are the trading details for Xvivo Perfusion AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: XVIVO
What kind of share is Xvivo Perfusion AB?

Based on an overall assessment of its quality, value and momentum, Xvivo Perfusion AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Xvivo Perfusion AB share price forecast 2020?

Shares in Xvivo Perfusion AB are currently priced at SEK185.4. At that level they are trading at 9.9% discount to the analyst consensus target price of 0.00.

Analysts covering Xvivo Perfusion AB currently have a consensus Earnings Per Share (EPS) forecast of 0.45 for the next financial year.

How can I tell whether the Xvivo Perfusion AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xvivo Perfusion AB. Over the past six months, the relative strength of its shares against the market has been 22.47%. At the current price of SEK185.4, shares in Xvivo Perfusion AB are trading at 17.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Xvivo Perfusion AB PE Ratio?

We were not able to find PE ratio data for Xvivo Perfusion AB.

Who are the key directors of Xvivo Perfusion AB?

Xvivo Perfusion AB's management team is headed by:

Magnus Nilsson - CEO
Christoffer Rosenblad - DCE
Folke Nilsson - IND
Gosta Johannesson - CHM
Par-Ola Larsson - OTH
Emur Jensen - OTH
Camilla Oberg - IND
Yvonne Martensson - DRC
Alan Raffensperger - DRC
Henrik Isaksson - COO
Dag Andersson - DRC
Who are the major shareholders of Xvivo Perfusion AB?

Here are the top five shareholders of Xvivo Perfusion AB based on the size of their shareholding:

Bure Equity AB Private Equity
Percentage owned: 15.81% (4.21m shares)
Swedbank Robur Ny Teknik Mutual Fund
Percentage owned: 6.91% (1.84m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 6.13% (1.63m shares)
Eccenovo AB Corporation
Percentage owned: 5.64% (1.50m shares)
Norron Asset Management AB Investment Advisor
Percentage owned: 4.78% (1.27m shares)
Similar to XVIVO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.